Key result
Potent P2Y12 inhibitors linked to ~27% lower thrombotic risk vs clopidogrel in post-MI CYP2C19 normal metabolizers.
Why the study?
Do potent P2Y12 inhibitors reduce ischaemic events in CYP2C19 normal metabolisers presenting with myocardial infarction and undergoing PCI compared to clopidogrel?
Do potent P2Y12 inhibitors reduce ischaemic events in CYP2C19 normal metabolisers presenting with myocardial infarction and undergoing PCI compared to clopidogrel?
In CYP2C19 normal metabolizers with myocardial infarction undergoing PCI, potent P2Y12 inhibitors are associated with a reduction in ischemic events without a significant increase in major bleeding compared to clopidogrel.
Answers are grounded in this paper and cite their sources.
Supports potent P2Y12 inhibitors in CYP2C19 normal metabolizers post-MI PCI; extends RCT evidence but remains hypothesis-generating pending dedicated trials.
We thank the correspondents for their constructive comments and for the opportunity to clarify several important aspects of our study. First, we acknowledge that the 2004 to 2020 recruitment period spans different eras of percutaneous coronary intervention practice and evolving dual antiplatelet therapy strategies. To address this concern, we conducted a sensitivity analysis excluding patients treated before 2012, when potent P2Y₁₂ inhibitors became consistently adopted in Taiwan. The results were directionally consistent with the primary analysis (HR 0.76; 95% CI 0.56 to 1.04), supporting the robustness of our findings across treatment eras. Second, we recognize the possibility of residual confounding, including medication adherence and socioeconomic status, which cannot be fully eliminated in observational research. To mitigate adherence-related bias, we performed an as-treated analysis, censoring patients at treatment crossover. This analysis likewise demonstrated a reduced thrombotic risk with potent P2Y₁₂ inhibitors (HR 0.73; 95% CI 0.56 to 0.96). The concordance of findings across intention-to-treat, as-treated and propensity score matched analyses strengthens the internal validity of our conclusions. Nevertheless, prospective studies incorporating standardized adherence measures remain warranted. Third, this study utilized pre-existing genetic test results from the China Medical University Hospital database. These data were obtained retrospectively and were not generated at the time of PCI to inform immediate antiplatelet decision-making. In routine clinical practice, antiplatelet selection was primarily based on the treating physician's judgement and contemporaneous international and local guideline recommendations. Fourth, only hospitalized bleeding events were captured in this study. This approach may underestimate the overall incidence of bleeding and constitutes a study limitation. Hospitalization-defined bleeding was selected as the safety endpoint because of its higher reliability and coding accuracy within the database. This definition was applied symmetrically across both treatment groups and is therefore unlikely to introduce systematic bias; however, it may have led to under-ascertainment of milder or outpatient-managed bleeding events. In addition, characteristics of Taiwan's National Health Insurance system, including streamlined access to care and structured follow-up, may have contributed to a lower overall bleeding incidence in both groups. Importantly, our findings indicate that among CYP2C19 normal metabolisers presenting with myocardial infarction and undergoing PCI, initiation of potent P2Y₁₂ inhibitors was associated with a reduction in ischaemic events without a significant increase in major bleeding. These data do not support routine de-escalation to clopidogrel in this population. Rather, potent P2Y₁₂ inhibitors should be preferentially considered. Evaluation of de-escalation strategies may be more appropriate in carefully selected subgroups with lower ischaemic risk and higher bleeding risk, ideally within prospective trials. Hsing-Yu Hsu: Conceptualization; data curation; formal analysis; visualization; drafting of the manuscript. Shih-Sheng Chang: Methodology; data interpretation; critical revision of the manuscript. Ke-Wei Chen: Investigation; data validation. Kuan-Cheng Chang: Clinical supervision; interpretation of findings; critical revision of the manuscript. Fuu-Jen Tsai: Study supervision; funding acquisition; final approval of the manuscript. The authors declare no conflicts of interest and no commercial funding. Yours sincerely, The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2026) conducted a letter in Myocardial infarction undergoing percutaneous coronary intervention. Potent P2Y12 inhibitors vs. Clopidogrel was evaluated on Thrombotic risk (HR 0.73, 95% CI 0.56-0.96). Among CYP2C19 normal metabolizers with myocardial infarction undergoing PCI, potent P2Y12 inhibitors reduced thrombotic risk compared to clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: